Literature DB >> 10473198

Comparison of 225actinium chelates: tissue distribution and radiotoxicity.

I A Davis1, K A Glowienka, R A Boll, K A Deal, M W Brechbiel, M Stabin, P N Bochsler, S Mirzadeh, S J Kennel.   

Abstract

The biodistribution and tissue toxicity of intravenously administered 225-actinium (225Ac) complexed with acetate, ethylene diamine tetraacetic acid (EDTA), 1, 4, 7, 10, 13-pentaazacyclopentadecane-N, N', N", N"', N""-pentaacetic acid (PEPA), or the "a" isomer of cyclohexyl diethylenetriamine pentaacetic acid (CHX-DTPA), were examined. The percent of injected dose per organ and per gram of tissue for each chelate complex was determined. 225Ac-CHX-DTPA was evaluated further for radiotoxic effects. Mice receiving > or =185 kBq 225Ac-CHX-DTPA suffered 100% morbidity by 5 days and 100% mortality by 8 days postinjection, and all animals evaluated had significant organ damage. The in vivo instability of the 225Ac-CHX-DTPA complex likely allowed accumulation of free 225Ac in organs, which resulted in tissue pathology.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10473198     DOI: 10.1016/s0969-8051(99)00024-4

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  17 in total

Review 1.  An overview of targeted alpha therapy.

Authors:  Young-Seung Kim; Martin W Brechbiel
Journal:  Tumour Biol       Date:  2011-12-06

2.  Actinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches.

Authors:  Nikki A Thiele; Justin J Wilson
Journal:  Cancer Biother Radiopharm       Date:  2018-06-11       Impact factor: 3.099

3.  Efficient 1-step radiolabeling of monoclonal antibodies to high specific activity with 225Ac for α-particle radioimmunotherapy of cancer.

Authors:  William F Maguire; Michael R McDevitt; Peter M Smith-Jones; David A Scheinberg
Journal:  J Nucl Med       Date:  2014-06-30       Impact factor: 10.057

4.  Branched amphiphilic peptide capsules: cellular uptake and retention of encapsulated solutes.

Authors:  Pinakin Sukthankar; L Adriana Avila; Susan K Whitaker; Takeo Iwamoto; Alfred Morgenstern; Christos Apostolidis; Ke Liu; Robert P Hanzlik; Ekaterina Dadachova; John M Tomich
Journal:  Biochim Biophys Acta       Date:  2014-02-22

Review 5.  Actinium-225 in targeted alpha-particle therapeutic applications.

Authors:  David A Scheinberg; Michael R McDevitt
Journal:  Curr Radiopharm       Date:  2011-10

Review 6.  Cancer radioimmunotherapy with alpha-emitting nuclides.

Authors:  Olivier Couturier; Stéphane Supiot; Marie Degraef-Mougin; Alain Faivre-Chauvet; Thomas Carlier; Jean-François Chatal; François Davodeau; Michel Cherel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05       Impact factor: 9.236

7.  H2BZmacropa-NCS: A Bifunctional Chelator for Actinium-225 Targeted Alpha Therapy.

Authors:  Karthika J Kadassery; A Paden King; Stanley Fayn; Kwamena E Baidoo; Samantha N MacMillan; Freddy E Escorcia; Justin J Wilson
Journal:  Bioconjug Chem       Date:  2022-06-07       Impact factor: 6.069

Review 8.  Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications.

Authors:  Matthias Miederer; David A Scheinberg; Michael R McDevitt
Journal:  Adv Drug Deliv Rev       Date:  2008-04-23       Impact factor: 15.470

Review 9.  Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight".

Authors:  Romain Eychenne; Michel Chérel; Férid Haddad; François Guérard; Jean-François Gestin
Journal:  Pharmaceutics       Date:  2021-06-18       Impact factor: 6.321

Review 10.  A Critical Review of Alpha Radionuclide Therapy-How to Deal with Recoiling Daughters?

Authors:  Robin M de Kruijff; Hubert T Wolterbeek; Antonia G Denkova
Journal:  Pharmaceuticals (Basel)       Date:  2015-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.